Jian Ding, M.D.

Professor and former Director, Shanghai Institute of Materia Medica, Chinese Academy of Science; Member, National Academy of Engineering, P.R. China.

Dr. Ding received his M.D. from Kyushu University (Fukuoka, Japan) and has been working at Shanghai Institute of Materia Medica since 1992. He is the editor-in-chief of Acta Pharmacol Sinica. He published more than160 papers and won multiple national scientific achievement awards of P.R. China. He is an authority in the study of cancer biology and cancer pharmacology.

Jun Qin, Ph.D.

Professor, Department of Biochemistry and Molecular Biology, Baylor College of Medicine; Director, Beijing Proteome Research Center, Beijing.

Dr. Qin received his B.S. in Chemistry from Tsinghua University, Beijing, and a Ph.D. at the Rockefeller University. He is a preeminent researcher of proteomics, DNA damage repair, nuclear receptor functions, and biomarker discovery. His laboratory recently worked out a complete workflow for efficient identification of endogenous protein complexes and streamlined workflows for rapid analysis of mammalian proteomes and for quantification of protein expressions among tissues samples.

Yingming Zhao, Ph.D.

Professor, Ben May Department for Cancer Research at The University of Chicago.

Dr. Zhao received his Ph.D. at the Rockefeller University and pursued his independent career after his Ph.D.. He made seminal contributions to the fields of protein post-translational modifications and epigenetics by discovering seven types of new lysine acylation pathways and identifying about 250 new histone marks. His laboratory uses proteomics approaches in combination with pathology and biochemistry to understand mechanisms of action and to identify biomarkers for clinical drugs and drug candidates.

Steve A. Carr, Ph.D.

Director, of the Proteomics Platform at the Broad Institute of MIT and Harvard.

Dr. Carr received his Ph.D. from the Massachusetts Institute of Technology.  He is an international leader on developing and using mass spectrometry-based proteomic technologies for biomarker discovery, and for detecting and quantifying protein post-translational modifications. He has co-authored over 225 peer-reviewed publications on the development and use of proteomics and biological mass spectrometry. Dr. Carr also serves as associate editor of Molecular and Cellular Proteomics and on the editorial boards of Analytical Chemistry and Protein Science.

Brian T. Chait, D.PHIL

Camille and Henry Dreyfus Professor, the Rockefeller University

Dr. Chait received his Ph.D. from the University of Oxford. He is a pioneer in developing mass spectrometers for analyzing proteins, and diverse biological mass spectrometric and mass spectrometry-based proteomic technologies for studying various biological and biochemical phenomena. He serves as the director for the NIH-designated National Resource for the Mass Spectrometric Analysis of Biological Macromolecules.  Dr. Chait has received multiple awards to recognize his outstanding scientific achievements. He was also awarded 25 patents for his inventions.